-0.28%
-2.39%
-22.04%
-5.12%
51.98%
92.17%
48.62%
AI Spotlight on RVMD
Company Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers.The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors.
In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants.Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON).The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630.
Revolution Medicines, Inc.was incorporated in 2014 and is headquartered in Redwood City, California.
Market Data
| Last Price | 42.95 |
| Change Percentage | -0.28% |
| Open | 43.11 |
| Previous Close | 43.07 |
| Market Cap ( Millions) | 7832 |
| Volume | 1351251 |
| Year High | 62.4 |
| Year Low | 27.46 |
| M A 50 | 46.73 |
| M A 200 | 44.14 |
Financial Ratios
| FCF Yield | -7.04% |
| Dividend Yield | 0.00% |
| ROE | -33.67% |
| Debt / Equity | 5.54% |
| Net Debt / EBIDTA | 18.23% |
| Price To Book | 4.58 |
| Price Earnings Ratio | -12.64 |
| Price To FCF | -14.21 |
| Price To sales | 10555.17 |
| EV / EBITDA | -12.28 |
News
- Jan -29 - Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
- Jan -16 - Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Jan -06 - Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
- Dec -15 - Insiders Are Loving These 6 Stocks Right Now
- Dec -05 - Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Dec -04 - Revolution Medicines: Risky Buy On Recent Share Price Dip
- Dec -04 - Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- Dec -02 - Revolution Medicines Announces Commencement of Public Offering of Common Stock
- Dec -02 - Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
- Nov -27 - Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
- Nov -07 - Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
- Nov -06 - Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
- Nov -05 - Revolution Medicines to Participate in Upcoming Investor Conferences
- Oct -30 - Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
- Oct -25 - Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
- Oct -23 - Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
- Oct -21 - Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Oct -07 - Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
- Aug -11 - Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript
- Aug -07 - Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Targeted Therapies
Expected Growth : 10.43 %
What the company do ?
Novel Targeted Therapies from Revolution Medicines, Inc. are innovative treatments that selectively target specific cancer-causing genes and proteins, offering new hope for cancer patients.
Why we expect these perspectives ?
Revolution Medicines' novel targeted therapies drive 10.43% growth, fueled by increasing adoption in cancer treatment, advancements in precision medicine, and a strong pipeline of innovative candidates. Additionally, strategic partnerships, expanding research and development efforts, and a growing demand for personalized therapies contribute to the company's rapid expansion.
Revolution Medicines, Inc. Products
| Product Range | What is it ? |
|---|---|
| RMC-4630 | RMC-4630 is a small molecule inhibitor of SHP2, a key node in multiple signaling pathways, including RAS and PI3K/AKT, that are commonly altered in cancer. |
| RMC-5552 | RMC-5552 is a potent and selective inhibitor of mTORC1, a key regulator of cell growth and metabolism. |
| RMC-6236 | RMC-6236 is a small molecule inhibitor of KRAS(G12C), a common oncogenic mutation in non-small cell lung cancer and other solid tumors. |
| RMC-6291 | RMC-6291 is a small molecule inhibitor of mTORC1/2, a key regulator of cell growth and metabolism. |
| RMC-4620 | RMC-4620 is a small molecule inhibitor of SHP2, a key node in multiple signaling pathways, including RAS and PI3K/AKT, that are commonly altered in cancer. |
Revolution Medicines, Inc.'s Porter Forces
Threat Of Substitutes
Revolution Medicines, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and genetic diseases.
Bargaining Power Of Customers
Revolution Medicines, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative options for patients.
Bargaining Power Of Suppliers
Revolution Medicines, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment.
Threat Of New Entrants
Revolution Medicines, Inc. has a high threat of new entrants due to the growing demand for cancer and genetic disease treatments and the presence of venture capital funding for biotech startups.
Intensity Of Rivalry
Revolution Medicines, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 4.59% |
| Debt Cost | 3.95% |
| Equity Weight | 95.41% |
| Equity Cost | 11.20% |
| WACC | 10.87% |
| Leverage | 4.82% |
Revolution Medicines, Inc. : Quality Control
Revolution Medicines, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| DNLI | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, … |
| IONS | Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for … |
| JANX | Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product … |
| FOLD | Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the … |
| IOVA | Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Denali Therapeutics
A-Score
1-Year Total Return ->
🥈
Revolution Medicines
A-Score
1-Year Total Return ->
🥉
Janux Therapeutics
A-Score
1-Year Total Return ->
4
Amicus Therapeutics
A-Score
1-Year Total Return ->
5
Ionis Pharmaceuticals
A-Score
1-Year Total Return ->
6
